Alexithymia and immunoendocrine parameters in patients affected by systemic lupus erythematosus and rheumatoid arthritis;Alessitimia e pathway immunoendocrino nel lupus eritematoso sistemico e nell'artrite reumatoide

Reumatismo

Volumn 60, Issue 1, 2008, Pages 50-56

  Vadacca, Marta ^a   Bruni, R ^a   Cacciapaglia, F ^a   Serino, F ^a   Arcarese, L ^a   Buzzulini, F ^a   Coppolino, G ^a   Rigon, A ^a   Terminio, N ^a   Afeltra, A ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Alexithymia; Immunoendocrine parameters; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; HUMAN GROWTH HORMONE; HYDROXYCHLOROQUINE; INTERLEUKIN 6; METHOTREXATE; PROLACTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALEXITHYMIA; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH HORMONE BLOOD LEVEL; HUMAN; IMMUNOMODULATION; MONOTHERAPY; PREVALENCE; PROTEIN BLOOD LEVEL; RATING SCALE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TORONTO ALEXITHYMIA SCALE 20;

ADULT; AFFECTIVE SYMPTOMS; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PREVALENCE;

EID: 57149126132     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lumley MA, Radcliffe AM, Macklem DJ, Masley-Williams A, Leisen J, Huffman J, et al. Alexithymia and pain in three chronic pain samples: comparing Caucasians and African Americans. Pain Med 2005; 6: 251-61.
2. Kozora E, Ellison MC, West S. Depression, fatigue and pain in systemic lupus erythematous (SLE): Relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum 2006; 55: 628-35.
3. Taylor GJ, Bagby RM, Parker JDA. The alexithymia construct: A potential paradigm for psychosomatic medicine. Psychosomatics 1991; 32: 153-64.
4. Sifneos PE. The prevalence of 'alexithymic' characteristics in psychosomatic patients. Psychother Psychosom 1973; 22: 255-62.
5. Van de Putte EM, Engelbert RH, Kuis W, Kimpen JL, Uiterwaal CS. Alexithymia in adolescents with chronic fatigue syndrome. J Psychosom Res 2007; 63: 377-80.
6. Richards HL, Fortune DG, Griffiths CE, Main CJ. Alexithymia in patients with psoriasis: Clinical correlates and psychometric properties of the Toronto Alexithymia Scale-20. J Psychosom Res 2005; 58: 89-96.
7. Mehling WE, Krause N. Are difficulties perceiving and expressing emotions associated with low-back pain? The relationship between lack of emotional awareness (alexithymia) and 12-month prevalence of low-back pain in 1180 urban public transit operators. J Psychosom Res 2005; 58: 73-81.
8. Dewaraja R, Tanigawa T, Araki S, Nakata A, Kawamura N, Ago Y, Sasaki Y. Decreased cytotoxic lymphocyte counts in alexithymia. Psychother Psychosom 1997; 66: 83-6.
9. van Middendorp RG, Sorbi MJ, van Doornen LJP, JWJ Bijlsma. Emotion regulation predicts change of perceived health in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1071-4.
10. Corcos M, Guilbaud O, Paterniti S, Curt F, Hjalmarsson L, Moussa M, et al. Correlation between serum levels of interleukin-4 and alexithymia scores in healthy female subjects: Preliminary results. Psychoneuroendocrinology 2004; 29: 557-62.
11. Jara LJ, Navarro C, Medina G, Vera-Lastra O, Blanco F. Immune-neuroendocrine interactions and autoimmune diseases. Clin Dev Immunol 2006; 13: 109-23.
12. Wilder RL. Neuroimmunoendocrinology of the rheumatic diseases: Past, present, and future. Ann N Y Acad Sci 2002; 966: 13-9.
13. Sternberg EM. Neuroendocrine regulation of autoimmune/inflammatory disease. J Endocrinol. 2001; 169: 429-35.
14. Ram S, Blumberg D, Newton P, Anderson NR, Gama R. Raised serum prolactin in rheumatoid arthritis: Genuine or laboratory artefact? Rheumatology 2004; 43: 1272-4.
15. Jara LJ, Pacheco-Reyes H, Medina G, Angeles U, Cruz-Cruz P, Saavedra MA. Prolactin levels are associated with lupus activity, lupus anticoagulant, and poor outcome in pregnancy. Ann N Y Acad Sci. 2007; 1108: 218-26.
16. Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 2007; 6: 537-42.
17. Köller MD, Templ E, Riedl M, Clodi M, Wagner O, Smolen JS, Luger A. Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus. Ann Rheum Dis. 2004; 63: 1677-80.
18. Blackman MR, Muniyappa R, Wilson M, Moquin BE, Baldwin HL, Wong KA, et al. Diurnal secretion of growth hormone, cortisol, and dehydroepiandrosterone in pre- and perimenopausal women with active rheumatoid arthritis: A pilot case-control study. Arthritis Res Ther. 2007; 28: 9: R73.
19. Eijsbouts AM, van den Hoogen FH, Laan RF, Hermus AR, Sweep CG, van de Putte LB. Hypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005; 23: 658-64.
20. Correa SG, Maccioni M, Rivero VE, Iribarren P, Sotomayor CE, Riera CM. Cytokines and the immuneneuroendocrine network: What did we learn from infection and autoimmunity? Cytokine Growth Factor Rev 2007; 18: 125-34.
21. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
23. Bombardieri C, Gladman DD, Urowitz BD, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis studies in SLE. Arthritis Rheum 1992; 35: 630-40.
24. Bagby RM, Parker JDA, Taylor GJ. The twenty-item Toronto Alexithymia Scale: I Item selection and cross-validation of the factor structure. J Psychosom Res 1994; 38: 23-32.
25. Bagby RM, Taylor GJ, Parker JDA. The twenty-item Toronto Alexithymia Scale: II Convergent, discriminant and concurrent validity. J Psychosom Res 1994; 38: 33-40.
26. Taylor GJ. Psychosomatics and self-regulation. In: JW Barron, MN Eagle, DL Wolitzky. Interface of Psychoanalysis and Psychology. American Psychological Association, Washington 1992; 464-88.
27. Bruni R, Serino FM, Galluzzo S, Coppolino G, Cacciapaglia F, Vadacca M, et al. Alexithymia and neuroendocrine- immune response in patients with autoimmune diseases: Preliminary results on relationship between alexithymic construct and TNF-alpha levels. Ann N Y Acad Sci 2006; 1069: 208-11.
28. Dorshkind K, Horseman ND. The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: Insights from genetic models of hormone and hormone receptor deficiency. Endocr Rev 2000; 21: 292-312.
29. Dorshkind K, Horseman ND. Anterior pituitary hormones, stress, and immune system homeostasis. Bioessays 2001; 23: 288-94.
30. Jara LJ, Vera-Lastra O, Miranda JM, Alcala M, Alvarez Nemegyei J. Prolactin in human systemic lupus erythematosus. Lupus 2001; 10: 748-56.
31. Vera-Lastra O, Jara LJ, Espinoza LR. Prolactina and autoimmunity. Autoimmunity reviews 2002; 1: 360-4.
32. Buckley TM, Schatzberg AF. On the interactions of the hypothalamic-pitituary-adrenal (HPA) axis and sleep: Normal HPA axis activity and circadian rhytm, exemplary sleep disorders. J Clin Endocrinol Metab 2005; 90: 3106-12.
33. Guilbaud O., M. Corcos, L Hjalmarsson, G Loas, P Jeammet. Is there a psychoneuroimmunological pathway between alexithymia and immunity? Immune and physiological correlates of alexithymia. Biomedicine Pharmacotherapy 2003; 57: 292-5.